Berkeley Lights and the Icahn Institute at Mount Sinai Announce Single Cell Annotation and Genomics Collaboration Program as First BioFoundry Partner

The Icahn Institute is the first BioFoundry™ lab partner implementing Berkeley Lights' OptoSelect™ Light Technology

Dec 10, 2015, 09:00 ET from Berkeley Lights, Inc.

EMERYVILLE, Calif., Dec. 10, 2015 /PRNewswire/ -- Berkeley Lights, Inc., the pioneer in opto-nanofluidic biosystems that enable interactive biology at the cellular level, today announced it has signed an agreement with the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai that provides early access to Berkeley Lights' instrumentation incorporating its OptoSelect™ light technology* for single cell annotation and genomics. Mount Sinai is using Berkeley Lights' instruments to advance research into applications that will help to transform healthcare.

"The OptoSelect high throughput method provides our team a single cell manipulation platform for exploring otherwise unachievable applications in immunotherapy, single cell genomics, diagnostics, and in-depth, accurate analysis of tissue heterogeneity," stated Robert Sebra, PhD, Director of Technology Development at the Icahn Institute and Assistant Professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai. 

Single cell biology is a rapidly growing field within life sciences that is taking genomic testing to the next level. Historically, a sample has consisted of many types of cells in groups of tens of thousands of cells.  Berkeley Lights' OptoSelect technology* enables a new level of automation and precision for single cell analysis research. By accepting a broad spectrum of cell densities and isolating them in a non-destructive manner, the OptoSelect technology provides flexibility across a range of applications, including those that require selection or manipulation of low input to rare cell populations.  Very small, precious samples such as fine needle aspirates can now be sorted, annotated, and tested automatically and accurately. Biologists can now select the types of cells and number of cells to interrogate, which allows them to see genomic variations at the cellular level, allowing for the identification of the true drivers of a cell population.

"We are excited to have the Icahn Institute at Mount Sinai as our first BioFoundry partner.  Their vast expertise in the area of single cell genomics is now being exercised on our instruments to generate fundamental knowledge and information that will help guide development of future diagnostic tests," stated Igor Khandros, PhD, Berkeley Lights CEO and co-founder.  "Berkeley Lights is ushering in a new era of interactive biology that will lead to actionable understanding of diseases."

"Berkeley Lights is the only available technology where you can truly 'see' numerous single, distinct cells, and monitor in real time each cell's function during biochemistry or other manipulations," said Eric Schadt, PhD, the Jean C. and James W. Crystal Professor of Genomics at the Icahn School of Medicine at Mount Sinai, and Founding Director of the Icahn Institute for Genomics and Multiscale Biology.

BLI's OptoSelect light technology automates challenging tasks in research applications such as tumor profiling-morphology, surface markers, sequence and protein secretions of single cells from fine needle aspirates (FNAs) and other precious samples.  BLI's nanofluidic Biosystems also enable the selection with high purity of very rare single cells, such as circulating tumor cells (CTCs).  It applies advanced semiconductor technology for nano-fluidics that drives the precision in genomic data and advancements in automation and integration of workflows.

* For Research Use Only.  Not for use in diagnostic procedures.

About Berkeley Lights
Berkeley Lights opto-nanofluidic platforms are enabling interactive biology at the cellular level and empowering scientists and researchers to study and interact with single cells in ways never before possible. Headquartered in Emeryville, California, Berkeley Lights is working with biopharma and biotech companies to facilitate drug discovery and cell line development, and with research institutes on single-cell annotation and genomics. For more information, visit

About the Mount Sinai Health System
The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community-based facilities to tertiary and quaternary care.

The System includes approximately 6,100 primary and specialty care physicians; 12 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. Physicians are affiliated with the renowned Icahn School of Medicine at Mount Sinai, which is ranked among the highest in the nation in National Institutes of Health funding per investigator. The Mount Sinai Hospital is nationally ranked as one of the top 25 hospitals in 8 specialties in the 2014-2015 "Best Hospitals" issue of U.S. News & World Report. Mount Sinai's Kravis Children's Hospital also is ranked in seven out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked nationally, while Mount Sinai Beth Israel, Mount Sinai St. Luke's, and Mount Sinai Roosevelt are ranked regionally.

For more information, visit or find Mount Sinai on Facebook, Twitter and YouTube.

Logo -


SOURCE Berkeley Lights, Inc.